Furthermore, upregulation of CHAF1B increased the viability, clonal formation and anti-apoptosis ability of HCC cells treated with sorafenib, whereas silencing CHAF1B resulted in enhanced cell viability and clonal formation, along with increased anti-apoptotic capabilities. This evidence concerns the gene CHAF1B and hepatocellular carcinoma.